



ADULT MEDICATION GUIDELINE

Amiodarone

Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

[HIGH RISK Medication](#) 

Medication Class

Antiarrhythmic

Presentation

Ampoule: 150mg/3mL

Tablet: 200mg

Storage

Ampoule: Store below 25°C. Protect from light.

Tablet: Store below 30°C. Protect from light.

Dose

IV Bolus Dosing (in Medical Emergency Situations Only)

Refer to [KEMH Adult Resuscitation Drug Protocols](#)

Bolus doses are generally not recommended because of the risk of severe hypotension and circulatory collapse. Bolus doses should only be administered in medical emergency situations under close supervision and guidance of a senior medical officer

IV Infusion Dose

Refer to [SCGOPHCG Amiodarone Guideline](#)

Administration

IV Infusion

Refer to [SCGOPHCG Amiodarone Guideline](#)

Amiodarone is adsorbed onto PVC and leaches plasticiser from PVC. For continuous infusions that will exceed 2 hours, the solution must be prepared in polyolefin bag (Freeflex), rigid PVC bottle (e.g Braun), non-PVC burettes or Baxter Viaflo. The use of non-PVC bags is recommended for all infusions at WNHS

Monitoring

ECG, Blood pressure, Vital signs and as per anaesthetics

Pregnancy

Amiodarone should not be given to pregnant mothers unless critically required. Thyroid function of newborn should be assessed.

1st Trimester: Consider alternative

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Monitoring required

Regular laboratory monitoring of the infant's amiodarone plasma level and cardiac and thyroid function are also recommended.

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Related Policies, Procedures & Guidelines

[SCGOPHCG Amiodarone Guideline](#)

WNHS Clinical Practice Guidelines:

[Acute Deterioration \(Adult\): Resuscitation and Life Support](#)

[Adult Resuscitation Drug Protocols](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[High Risk Medicines](#)

[Pre-operative Medication Management](#)

References

[FSH Amiodarone Guideline](#)

Australian Medicines Handbook. Amiodarone. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2022 April 07]. Available from: <https://amhonline.amh.net.au/>

MIMS Australia. Amiodarone GH Injection. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2018 [cited 2022 April 07]. Available from: <https://www.mimsonline.com.au>

MIMS Australia. Cordarone X Tablets. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2022 [cited 2022 April 07]. Available from: <https://www.mimsonline.com.au>

Society of Hospital Pharmacists of Australia. Amiodarone. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2017 [cited 2022 April 07]. Available from: <http://aidh.hcn.com.au>

Therapeutic Guidelines. Cardiovascular: Tachyarrhythmias. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2022 [cited 2022 April 07]. Available from: <https://tgldcdp.tg.org.au>

The Royal Women's Hospital. Amiodarone. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2022 April 07]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Amiodarone, Cardiac Arrest, Resuscitation, Arrhythmia, SVT, VT				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0				
Date First Issued:	05/2015	Last Reviewed:	04/2022	Review Date:	04/2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	07/06/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.